- Home
- MFIN vs TCRX Comparison
MFIN vs TCRX Comparison
Compare MFIN & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFIN
- TCRX
- Stock Information
- Founded
- MFIN 1995
- TCRX 2018
- Country
- MFIN United States
- TCRX United States
- Employees
- MFIN N/A
- TCRX N/A
- Industry
- MFIN Finance: Consumer Services
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- MFIN Finance
- TCRX Health Care
- Exchange
- MFIN Nasdaq
- TCRX Nasdaq
- Market Cap
- MFIN 190.0M
- TCRX 170.1M
- IPO Year
- MFIN 1996
- TCRX 2021
- Fundamental
- Price
- MFIN $8.92
- TCRX $2.43
- Analyst Decision
- MFIN
- TCRX Strong Buy
- Analyst Count
- MFIN 0
- TCRX 5
- Target Price
- MFIN N/A
- TCRX $11.40
- AVG Volume (30 Days)
- MFIN 41.1K
- TCRX 285.2K
- Earning Date
- MFIN 02-18-2025
- TCRX 03-05-2025
- Dividend Yield
- MFIN 4.95%
- TCRX N/A
- EPS Growth
- MFIN N/A
- TCRX N/A
- EPS
- MFIN 1.69
- TCRX N/A
- Revenue
- MFIN $293,257,000.00
- TCRX $9,362,000.00
- Revenue This Year
- MFIN N/A
- TCRX N/A
- Revenue Next Year
- MFIN $11.69
- TCRX $5.14
- P/E Ratio
- MFIN $5.26
- TCRX N/A
- Revenue Growth
- MFIN 18.48
- TCRX N/A
- 52 Week Low
- MFIN $6.48
- TCRX $2.31
- 52 Week High
- MFIN $10.50
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- MFIN 38.12
- TCRX 33.69
- Support Level
- MFIN $8.72
- TCRX $2.39
- Resistance Level
- MFIN $9.62
- TCRX $2.67
- Average True Range (ATR)
- MFIN 0.29
- TCRX 0.16
- MACD
- MFIN -0.03
- TCRX 0.04
- Stochastic Oscillator
- MFIN 2.09
- TCRX 28.74
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. Its operating segments include recreation, home improvement, commercial lending, medallion lending and Corporate and Other Investments. The company generates maximum revenue from the Recreation segment.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.